Data gathered: November 27
AI Stock Analysis - Sarepta Therapeutics (SRPT)
Analysis generated October 1, 2024. Powered by Chat GPT.
Sarepta Therapeutics (NASDAQ: SRPT) is a biotechnology company specializing in the research and development of precision genetic medicine for rare diseases. The company focuses on developing therapies primarily for Duchenne Muscular Dystrophy (DMD), a severe type of muscular dystrophy. Over the years, Sarepta has established itself as a leader in the DMD space with its portfolio of RNA-targeted therapies. Despite recent fluctuations in their financial performance, the company remains a key player in the biotech sector, working on cutting-edge therapies that hold significant promise.
Stock Alerts - Sarepta Therapeutics (SRPT)
 |
Sarepta Therapeutics | November 27 Price is up by 5% in the last 24h. |
|
Sarepta Therapeutics | November 26 Price is up by 5.2% in the last 24h. |
|
Sarepta Therapeutics | November 15 Price is down by -5.1% in the last 24h. |
|
Sarepta Therapeutics | November 7 Price is down by -5.9% in the last 24h. |
Alternative Data for Sarepta Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 16 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 22,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 121 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 654 | Sign up | Sign up | Sign up |
| Facebook Followers | 9,242 | Sign up | Sign up | Sign up |
| Instagram Followers | 5,257 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 64 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,858 | Sign up | Sign up | Sign up |
| Twitter Followers | 5,703 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $83,000 | Sign up | Sign up | Sign up |
| Business Outlook | 85 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,469 | Sign up | Sign up | Sign up |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Price | $137.94 |
| Target Price | Sign up |
| Volume | 1,860,000 |
| Market Cap | $11B |
| Year Range | $104.54 - $163.85 |
| Dividend Yield | 0% |
| PE Ratio | 74.45 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from Analysts at HC WainwrightNovember 26 - ETF Daily News |
 |
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical ProgramsNovember 25 - Yahoo |
 |
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA ProgramsNovember 25 - Yahoo |
|
Mutual of America Capital Management LLC Sells 2,579 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)November 20 - ETF Daily News |
|
StockNews.com Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to HoldNovember 20 - ETF Daily News |
|
Aigen Investment Management LP Sells 7,994 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)November 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 467M | 129M | 338M | 34M | 40M | 0.340 |
| Q2 '24 | 363M | 139M | 224M | 6.5M | 19M | 0.070 |
| Q1 '24 | 413M | 128M | 286M | 36M | 46M | 0.370 |
| Q4 '23 | 397M | 135M | 262M | 46M | 46M | 0.470 |
| Q3 '23 | 332M | 149M | 183M | -41M | -28M | -0.460 |
Insider Transactions View All
| Estepan Ian Michael filed to sell 33,946 shares at $137.4. September 3 '24 |
| Chambers Michael Andrew filed to buy 284,034 shares at $134.7. August 20 '24 |
| Chambers Michael Andrew filed to buy 260,102 shares at $133.1. August 20 '24 |
| Chambers Michael Andrew filed to buy 278,386 shares at $134.1. August 20 '24 |
| Brown Ryan Edward filed to sell 45,267 shares at $160.3. June 25 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
Aug 21, 23 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Jul 11, 23 | Sell | $1K - $15K |
| Daniel S. Goldman Democrat |
May 19, 23 | Sell | $15K - $50K |
Read more about Sarepta Therapeutics (SRPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Sarepta Therapeutics?
The Market Cap of Sarepta Therapeutics is $11B.
What is Sarepta Therapeutics' PE Ratio?
As of today, Sarepta Therapeutics' PE (Price to Earnings) ratio is 74.45.
What is the current stock price of Sarepta Therapeutics?
Currently, the price of one share of Sarepta Therapeutics stock is $137.94.
How can I analyze the SRPT stock price chart for investment decisions?
The SRPT stock price chart above provides a comprehensive visual representation of Sarepta Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sarepta Therapeutics shares. Our platform offers an up-to-date SRPT stock price chart, along with technical data analysis and alternative data insights.
Does SRPT offer dividends to its shareholders?
As of our latest update, Sarepta Therapeutics (SRPT) does not offer dividends to its shareholders. Investors interested in Sarepta Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sarepta Therapeutics?
Some of the similar stocks of Sarepta Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.